Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Enveric Biosciences, Inc.

  • CAMBRIDGE, Massachusetts
  • Public · NASDAQ: ENVB
  • 6 employees
$6.6MMarket cap
$39.9MRevenue · FY2019
-$8.8MNet income
6Employees
ENVBNASDAQ
1995IPO

About Enveric Biosciences, Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2019
$39.9M
Net income
-$8.8M
Total assets
$5.1M
Market cap
$6.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ENVB

15-minute delayed · data by Polygon.io

Market cap
$6.6M
Open
Day range
Prev close
Volume
IPO date
Aug 24, 1995

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Enveric Biosciences, Inc..

Write a review
Explore

Similar companies

Browse all →